You have accessJournal of UrologyProstate Cancer: Advanced I1 Apr 2012680 PREDICTION OF FAVOURABLE OUTCOME AND RATIONAL INDICATION OF DOCETAXEL RECHALLENGE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER Matthias Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer, Jürgen Gschwend, and Hubert Kübler Matthias HeckMatthias Heck Munich, Germany More articles by this author , Mark ThalgottMark Thalgott Munich, Germany More articles by this author , Margitta RetzMargitta Retz Munich, Germany More articles by this author , Petra WolfPetra Wolf Munich, Germany More articles by this author , Tobias MaurerTobias Maurer Munich, Germany More articles by this author , Jürgen GschwendJürgen Gschwend Munich, Germany More articles by this author , and Hubert KüblerHubert Kübler Munich, Germany More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.762AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To identify predictors of favourable oncological outcome in metastatic castration-resistant prostate cancer (mCRPC) patients who are treated with docetaxel rechallenge following first-line chemotherapy with docetaxel. METHODS We retrospectively evaluated the oncological outcome of mCRPC patients who were treated with 3-weekly docetaxel (75mg/m2) at first-line chemotherapy and rechallenge plus prednisone/ prednisolone. The endpoints of oncological outcome were PSA-progression-free survival (PSA-PFS) and overall survival (OS) after initiation of docetaxel rechallenge. The effect of clinical variables on PSA-PFS and OS was statistically analysed by a log-rank test or Cox regression with hazard ratios. All analyses were performed using a 0.05 level of significance. RESULTS 47 patients were included on analysis. At a median follow-up of 25.8 months (range 9.8-89.8 months) after the first administration of docetaxel, 27 (57.4%) patients had died. Median PSA-PFS was 5.9 months (95% CI 3.5-6.8 months) and median OS was 21.4 months (95% CI 18.9-23.9 months) after initiation of docetaxel rechallenge. PSA-reduction ≥ 30% was the only pre-treatment variable that correlated significantly with prolonged PSA-PFS (p=0.03) and OS (p=0.002). Patients with PSA-reduction ≥ 30% at first-line chemotherapy showed a median OS of 21.8 months since initiation of docetaxel rechallenge in comparison to 4.5 months in patients with < 30% PSA-reduction. CONCLUSIONS Docetaxel rechallenge represents an active treatment option in selected docetaxel-pretreated patients with mCRPC. In this retrospective study, PSA-reduction ≥ 30% at first-line chemotherapy with docetaxel predicted superior PSA-PFS and OS in the rechallenge setting and might, therefore, present a rational indication for docetaxel rechallenge. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187Issue 4SApril 2012Page: e277 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.MetricsAuthor Information Matthias Heck Munich, Germany More articles by this author Mark Thalgott Munich, Germany More articles by this author Margitta Retz Munich, Germany More articles by this author Petra Wolf Munich, Germany More articles by this author Tobias Maurer Munich, Germany More articles by this author Jürgen Gschwend Munich, Germany More articles by this author Hubert Kübler Munich, Germany More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...